Skip to main content

Table 2 General characteristics of all participants

From: A personal acquisition time regimen of 68Ga-DOTATATE total-body PET/CT in patients with neuroendocrine tumor (NET): a feasibility study

Characteristics

Full-activity cohort (N = 19)

Low-activity cohort (N = 57)

x2/t

P value

Gender, %

  

2.60

0.11

 Male

8 (42.1)

36 (63.2)

  

 Female

11 (57.9)

21 (36.8)

  

Age, years

51.7 ± 13.7 [30.0–74.0]

53.6 ± 11.2 [30.0–80.0]

0.60

0.55

Weight, kg

62.3 ± 11.2 [45.0–90.0]

67.7 ± 13.4 [42.8–101.8]

1.58

0.12

Height, cm

165.1 ± 8.4 [152.0–183.0]

166.7 ± 7.5 [152.3–180.0]

0.78

0.44

BMI, kg/m2

22.7 ± 2.8 [17.3–27.6]

24.3 ± 4.1 [17.1–34.9]

1.58

0.12

Injection activity per weight, MBq/kg

1.9 ± 0.2 [1.6–2.3]

1.0 ± 0.1 [0.8–1.2]

25.83

 < 0.0001

Injection activity, MBq

120.4 ± 27.2 [88.7–204.9]

66.9 ± 11.3 [41.9–88.0]

12.14

 < 0.0001

Acquisition time, min

10

10

-

-

Primary tumor location, %

   

0.72

 Pelviabdominal

17 (89.5)

48 (84.2)

  

 Chest

2 (10.5)

9 (15.8)

  

AJCC grade, %

   

0.55

 G1

6 (31.6)

18 (31.6)

  

 G2

12 (63.2)

29 (50.8)

  

 G3 or NC

1 (5.3)

10 (17.5)

  
  1. Data were as mean ± SD [range]
  2. BMI Body mass index, AJCC American Joint Committee on Cancer, NC Neuroendocrine carcinoma